House of Lords
Earl Howe (Parliamentary Under Secretary of State (Quality), Health; Conservative)
I am today publishing two documents relating to the regulation of medical devices and other cosmetic interventions and stemming from the fraudulent use of non-medical grade silicone in the breast implants manufactured by the French company Poly Implant Prothèse (PIP).
The first document is my review of the actions of the MHRA and Department of Health in relation to PIP implants, announced by the Secretary of State for Health on
The review also found that the MHRA should identify ways of gathering better evidence on the safety of devices, broaden its approach to analysing reported problems with higher risk medical devices and find better ways of communicating with the public. The operation of the European regulatory system must improve and health professionals and providers also need to be better at reporting problems when they occur.
The second document is the Government's response to the House of Commons Health Committee: Sixteenth Report of Session 2010-12 Cm 8351. In this response, we welcome the committee's analysis of the problems relating to PIP implants and its many helpful suggestions. Some of these are already reflected in the report mentioned above. Other recommendations will be picked up in the further work of Sir Bruce Keogh's expert group on PIP implants, and in the separate review into the regulation of cosmetic interventions, also announced on